These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36843692)

  • 21. Mobile Apps to Improve Medication Adherence in Cardiovascular Disease: Systematic Review and Meta-analysis.
    Al-Arkee S; Mason J; Lane DA; Fabritz L; Chua W; Haque MS; Jalal Z
    J Med Internet Res; 2021 May; 23(5):e24190. PubMed ID: 34032583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review.
    Baumgartner A; Drame K; Geutjens S; Airaksinen M
    Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32098393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset.
    Webster R; Bullen C; Patel A; Selak V; Stepien S; Thom S; Rodgers A
    Int J Cardiol; 2017 Dec; 249():443-447. PubMed ID: 28986058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial.
    Lafeber M; Grobbee DE; Schrover IM; Thom S; Webster R; Rodgers A; Visseren FL; Bots ML; Spiering W
    Int J Cardiol; 2015 Feb; 181():193-9. PubMed ID: 25528311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statins for the primary prevention of cardiovascular disease.
    Taylor F; Huffman MD; Macedo AF; Moore TH; Burke M; Davey Smith G; Ward K; Ebrahim S
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004816. PubMed ID: 23440795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.
    Lopez-Lopez JP; Gonzalez AM; Lanza P; Lopez-Jaramillo P
    Vasc Health Risk Manag; 2023; 19():605-615. PubMed ID: 37719697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial.
    Mostaza JM; Suárez-Fernández C; Cosín-Sales J; Gómez-Huelgas R; Brotons C; Araujo FP; Borrayo G; Ruiz E;
    BMC Cardiovasc Disord; 2022 Dec; 22(1):560. PubMed ID: 36550424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease.
    Flowers N; Hartley L; Todkill D; Stranges S; Rees K
    Cochrane Database Syst Rev; 2014; 2014(12):CD010405. PubMed ID: 25474484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can a polypill one single tablet combat different cardiovascular risk factors?
    Rosenthal T
    J Am Soc Hypertens; 2018 May; 12(5):335-339. PubMed ID: 29573975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management of different cardiovascular risk factors with a combination tablet (polypill)].
    Bramlage P; März W; Westermann D; Weisser B; Wirtz JH; Zeymer U; Baumgart P; van Mark G; Laufs U; Krämer BK; Unger T
    Herz; 2018 May; 43(3):246-257. PubMed ID: 28341983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omega 6 fatty acids for the primary prevention of cardiovascular disease.
    Al-Khudairy L; Hartley L; Clar C; Flowers N; Hooper L; Rees K
    Cochrane Database Syst Rev; 2015 Nov; (11):CD011094. PubMed ID: 26571451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polypill Therapy in Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials.
    Hennawi HA; Ashraf MT; Zohaib M; Khan MK; Khan IA; Muhammadzai HZU; Memon RA; Sadiq U; Siddiqi A; Roomi S; Nair A
    Curr Probl Cardiol; 2023 Aug; 48(8):101735. PubMed ID: 37044270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis.
    Kandil OA; Motawea KR; Aboelenein MM; Shah J
    Front Cardiovasc Med; 2022; 9():880054. PubMed ID: 35498049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.
    Bahiru E; de Cates AN; Farr MR; Jarvis MC; Palla M; Rees K; Ebrahim S; Huffman MD
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD009868. PubMed ID: 28263370
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.